NUVB
HEALTHCARENuvation Bio Inc - Class A
$5.04+0.21 (+4.35%)PRE
Live · NYSE · May 8, Close
AI Insight
What's Moving NUVB Today?
No stock-specific AI insight has been generated for NUVB yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.57$9.75
$5.04
Fundamentals
Market Cap$1.8B
P/E Ratio—
EPS$-0.43
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin-1.0%
Debt / Equity—
Trading
Volume6.3M
Avg Volume (10D)—
Shares Outstanding347.2M
NUVB News
21 articles- Nuvation Bio Inc. Beat Analyst Profit Forecasts, And Analysts Have New EstimatesYahoo Finance·May 8, 2026
- Undervalued Penny Stocks To Watch In May 2026Yahoo Finance·May 6, 2026
- Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung CancerYahoo Finance·May 6, 2026
- Nuvation Bio to Participate in Upcoming Investor ConferencesYahoo Finance·May 5, 2026
- Nuvation Bio Q1 Earnings Call HighlightsMarketbeat·May 5, 2026
- Nuvation Bio Inc. Q1 2026 Earnings Call SummaryMoby·May 5, 2026
- Nuvation Bio (NUVB) Q1 2026 Earnings TranscriptMotley Fool·May 4, 2026
- Nuvation Bio Inc. (NUVB) Lags Q1 Earnings EstimatesYahoo Finance·May 4, 2026
- Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business UpdateYahoo Finance·May 4, 2026
- CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 ReleaseYahoo Finance·Apr 28, 2026
- Nuvation Bio Inc. (NUVB) Reports Next Week: Wall Street Expects Earnings GrowthYahoo Finance·Apr 27, 2026
- Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI®) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System CancersYahoo Finance·Apr 27, 2026
- A Look At Nuvation Bio’s Valuation After Recent Share Price SwingsYahoo Finance·Apr 23, 2026
- Nuvation Bio (NUVB) Stock More Than Doubles Year-on-YearYahoo Finance·Apr 22, 2026
- Are Options Traders Betting on a Big Move in Nuvation Bio Stock?Yahoo Finance·Apr 22, 2026
- Nuvation Bio Inc (NUVB): Take a Look at Glioma Revenue PotentialYahoo Finance·Apr 22, 2026
- /U P D A T E -- Nuvation Bio Inc./Yahoo Finance·Apr 21, 2026
- 5 Best Small-Cap Biotech Stocks According to Hedge FundsYahoo Finance·Apr 21, 2026
- Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026Yahoo Finance·Apr 20, 2026
- How Much Can Nuvation Bio (NUVB) Make From Ibtrozi Sales?Yahoo Finance·Apr 17, 2026
- Insider Sells 200K Shares of Biotech Company Nuvation Bio (NUVB)The Motley Fool·Apr 13, 2026
All 21 articles loaded
Price Data
Open$4.45
Previous Close$4.83
Day High$4.53
Day Low$4.38
52 Week High$9.75
52 Week Low$1.57
52-Week Range
$1.57$9.75
$5.04
Fundamentals
Market Cap$1.8B
P/E Ratio—
EPS$-0.43
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin-1.0%
Debt / Equity—
Trading
Volume6.3M
Avg Volume (10D)—
Shares Outstanding347.2M
About Nuvation Bio Inc - Class A
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, is focused on developing therapeutic candidates for oncology. The company is headquartered in New York, New York.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNYSE
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—